Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/MESO
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Mesoblast Limited (MESO) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

MESO trades at $13.28, down 4.8% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025 on $17.20 million revenue, though 2026 revenue grew to $120 million with a reduced loss. Recent FDA approval for a Ryoncil potency assay and completion of a Phase 3 back pain trial are positive developments. Analyst consensus is mixed with 45% buy ratings.
The outlook hinges on commercial execution; revenue growth is strong but profitability remains elusive. Key risks include high cash burn and competitive pressures. Upside depends on successful product launches and regulatory milestones. The stock presents a high-risk, high-reward opportunity for investors betting on the company's pipeline.
Read full analysis

Key Stats

  • Market Cap
    $1.79B
  • Volume
    615,686
  • Sector
    Health
  • 52W High
    $20.96
  • 52W Low
    $11.95
  • Typical Hold Time
    16 Days
  • Enterprise Value
    $1.87B
  • Div Yield
    -
  • Trading Activity
    -
$12.46
52W Low: $11.95
19 Oct 2026
52W High: $20.96
09 Jan 2026

Track Mesoblast Limited (MESO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Mesoblast Limited has traded between a low of $11.95 and a high of $20.96, highlighting its annual price range. Buy and sell Mesoblast Limited shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Most Recent News

Content is generated by Aura AI

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
3 hours ago
Na
Bullish
news icon
Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Oracle and AstraZeneca team up to use AI and real-world data to speed up clinical trials and improve patient care.

Oracle and AstraZeneca have entered a collaboration to combine AstraZeneca's scientific expertise with Oracle's AI, cloud, and real-world data capabilities. The partnership aims to accelerate clinical trials by helping clinicians identify eligible pa...

Market News
4 hours ago
PRNewsWire
Bullish
news icon
Oracle and AstraZeneca team up to use AI and real-world data to speed up clinical trials and improve patient care.

Ambarella grows 13.2% in Q2 FY2027, shifting to edge AI with new chips but faces profit and cash flow challenges.

Ambarella is transitioning from security camera chips to edge AI, expanding into automotive, robotics, and smart security with new 5nm chips and the X7 AI accelerator. In Q2 FY2027, revenue rose 13.2% to $108.1 million, driven by automotive and IoT s...

Market News
4 hours ago
Seeking Alpha
Bullish
news icon
Ambarella grows 13.2% in Q2 FY2027, shifting to edge AI with new chips but faces profit and cash flow challenges.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $1.79B
  • Volume
    615,686
  • Sector
    Health
  • 52W High
    $20.96
  • 52W Low
    $11.95
  • Typical Hold Time
    16 Days
  • Enterprise Value
    $1.87B
  • Div Yield
    -
  • Trading Activity
    -
$12.46
52W Low: $11.95
19 Oct 2026
52W High: $20.96
09 Jan 2026

Track Mesoblast Limited (MESO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Mesoblast Limited has traded between a low of $11.95 and a high of $20.96, highlighting its annual price range. Buy and sell Mesoblast Limited shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!